Glenmark Pharmaceuticals has been granted a patent for a method to treat allergic rhinitis in humans, particularly pediatric patients, using a fixed-dose nasal spray composition of mometasone furoate and olopatadine. The formulation specifies a weight ratio, dosage, and pH range for effective administration. GlobalData’s report on Glenmark Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Glenmark Pharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. Glenmark Pharmaceuticals's grant share as of July 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Method for treating allergic rhinitis with mometasone and olopatadine
The patent US12064442B2 outlines a method for treating allergic rhinitis and its associated symptoms through the nasal administration of a fixed-dose pharmaceutical composition. This composition combines mometasone furoate and olopatadine or its salt in specific weight ratios ranging from about 1:12 to about 1:53. The administration involves delivering 1 or 2 sprays per nostril at least once daily, with each spray containing approximately 600 mcg of olopatadine and between 25 mcg to 50 mcg of mometasone furoate. The formulation is designed to maintain a pH between 3.3 and 4.1 and is noted for its stability, with a total impurity content of no more than 1.0% after six months of storage under specified conditions.
Additionally, the patent specifies that the method can effectively reduce treatment-related adverse effects compared to the use of olopatadine alone, particularly addressing symptoms such as nasal congestion, rhinorrhea, itching, and sneezing. The claims also differentiate between seasonal and perennial allergic rhinitis, emphasizing the versatility of the treatment. The composition is further characterized by its low crystallization of olopatadine hydrochloride, ensuring efficacy and stability over time. Overall, the patent presents a comprehensive approach to managing allergic rhinitis through a well-defined pharmaceutical formulation and administration protocol.
To know more about GlobalData’s detailed insights on Glenmark Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
